Tactile Systems Technology reported fourth‑quarter 2025 revenue of $103.6 million, up 21% from $85.6 million in Q4 2024, and earnings per share of $0.46, beating the consensus estimate of $0.44 by $0.02. The earnings beat was driven by disciplined cost management and a favorable mix of high‑margin lymphedema products, which helped offset the modest growth in the airway‑clearance line.
The lymphedema segment generated $91.2 million in revenue, a 21% increase from the $75.8 million reported in Q4 2024, while the airway‑clearance segment contributed $12.4 million, up 66% from $7.4 million in the same period. The strong lymphedema performance reflects continued adoption of the company’s pneumatic compression devices and the integration of LymphaTech’s digital monitoring platform, which has expanded the customer base and increased usage rates.
Gross margin expanded to 78% of revenue, up from 75% a year earlier. The margin lift reflects pricing power in the lymphedema market, cost efficiencies from the LymphaTech acquisition, and improved collections, which together offset the higher cost of goods sold associated with the expanded product portfolio.
For fiscal 2026, Tactile raised its sales guidance to $357–$365 million and adjusted EBITDA to $49–$51 million, up from the prior year’s full‑year adjusted EBITDA of $44.8 million. Management cited stronger demand, a favorable reimbursement environment, and the impact of the LymphaTech acquisition as key drivers of the upside. The guidance also incorporates the new Medicare prior‑authorization requirement for pneumatic compression devices, effective April 13 2026, which the company has factored into its outlook.
The LymphaTech acquisition, completed in Q4 2025, was paid upfront $6.8 million in cash with potential milestone‑based consideration. The deal adds a digital monitoring platform that complements Tactile’s existing therapy devices, creating a more comprehensive solution for lymphatic dysfunction and expanding the company’s market reach.
Sheri Dodd, CEO, said, "In 2025, we executed with discipline against our core growth strategies, delivering double‑digit revenue growth, expanding gross margin and adjusted EBITDA, and generating strong cash flow, while continuing to strategically invest in people and workflow‑related processes to strengthen our business for scale." She added, "The commercial momentum we described during our last call persisted through the fourth quarter, and we delivered total Q4 revenue growth of 21% year‑over‑year, resulting in $103.6 million of revenue."
Piper Sandler upgraded Tactile from Neutral to Overweight and raised its price target to $35.00 from $20.00, citing the earnings beat, margin expansion, and raised guidance as evidence of strong execution and confidence in future growth. Other analysts have maintained or slightly increased their targets, reflecting a consensus that the company’s integrated solution and market position are solidifying.
The company faces a new Medicare prior‑authorization requirement for pneumatic compression devices, effective April 13 2026, which could slow adoption in the short term. However, management believes the acquisition of LymphaTech and the company’s pricing power will mitigate this headwind and sustain growth momentum.
Overall, Tactile’s Q4 2025 results and forward guidance signal robust demand, operational efficiency, and a strategic shift toward integrated solutions, positioning the company for continued expansion in the lymphatic and airway‑clearance markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.